Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a new therapeutic pathway for cancers driven by NRAS mutations. Findings suggest that interfering with specific protein interactions could disrupt signaling pathways associated with uncontrolled cell proliferation in malignancies lacking targeted treatments.
This article was originally published on MedicalXpress.com